High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.


:A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 180, and 80 mg/m2, respectively. The dose-limiting toxicity was cardiac toxicity. Objective tumor regression occurred in 14 of 18 evaluable cases, with a median duration of 3.5 months. Pharmacokinetic evaluation of melphalan in 20 patients revealed a dose-related increase in maximum plasma concentration (Cmax) and area under the curve (AUC). Perturbation of the melphalan plasma half-life and AUC, associated with severe toxicity, resulted when renal insufficiency occurred. The results suggest that high-dose combination cyclophosphamide, cisplatin, and melphalan produces frequent, rapid responses in breast cancer, melanoma, and sarcoma, although with significant extramedullary toxicity. The pharmacokinetics suggest that modification of the treatment schedule may result in a reduction of treatment-related toxicity.


Peters WP,Stuart A,Klotman M,Gilbert C,Jones RB,Shpall EJ,Gockerman J,Bast RC Jr,Moore JO




Has Abstract


1989-01-01 00:00:00












  • Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo.

    abstract::PSC-833, a non immunosuppressive analogue of cyclosporin A, is an effective modulator of the multidrug-resistant tumor phenotype. Since both PSC-833 and cyclosporin A also enhance the cytotoxicity of VP-16 against drug sensitive L1210 leukemia cells in vitro we compared these agents as modulators of VP-16 efficacy in ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Slater LM,Sweet P,Stupecky M,Osann K

    更新日期:1997-01-01 00:00:00

  • In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy.

    abstract:PURPOSE:The aim was to investigate in patients receiving doxorubicin whether any alteration in myocardial oxidative metabolism or blood flow as assessed by positron emission tomography (PET) could be observed either after the first dose of the drug, or during its chronic administration. METHODS:Six female non-heart-fa...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Nony P,Guastalla JP,Rebattu P,Landais P,Lievre M,Bontemps L,Itti R,Beaune J,Andre-Fouet X,Janier M

    更新日期:2000-01-01 00:00:00

  • A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.

    abstract::The orally bioavailable matrix metalloproteinase inhibitor MMI270 reduces tumour growth metastasis in preclinical models. We assessed the feasibility and pharmacokinetic interactions of combining MMI270 with 5-fluorouracil (5-FU) and folinic acid (FA). Entered into the study were 33 patients with advanced colorectal c...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章


    authors: Eatock M,Cassidy J,Johnson J,Morrison R,Devlin M,Blackey R,Owen S,Choi L,Twelves C

    更新日期:2005-01-01 00:00:00

  • High-dose adriamycin (ADM) and cis-platinum (DDP) in advanced soft-tissue sarcomas and invasive thymomas. A pilot study.

    abstract::Eighteen previously untreated patients with advanced unresectable or metastatic soft-tissue sarcomas (STS) and two patients with locally invasive thymoma were treated with a combination of adriamycin (ADM) 80 mg/m2 on day 1 and cis-platinum (DDP) 120 mg/m2 on day 1. The regimen was repeated at 4-weeks intervals. In ST...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Klippstein TH,Mitrou PS,Kochendörfer KJ,Bergmann L

    更新日期:1984-01-01 00:00:00

  • Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.

    abstract::Levels of radioactivity and total anthracycline fluorescence in tissues of A/JAX mice were compared 1 h after IV administration of unlabeled or [14C]-labeled AD 32 (50 mg/kg). Highest levels of both fluorescence and radioactivity were found in the small intestine (including contents) and liver, a result consistent wit...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Israel M,Karkowsky AM,Khetarpal VK

    更新日期:1981-01-01 00:00:00

  • Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

    abstract::N2,N4,N6-Trihydroxymethyl-N2,N4,N6-trimethylmelamine (Trimelamol) is a water-soluble synthetic s-triazine which, unlike hexamethylmelamine (HMM) and pentamethylmelamine (PMM), does not require metabolic activation. The physico-chemical characteristics of Trimelamol were studied with the aim of overcoming the problems ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Rutty CJ,Judson IR,Abel G,Goddard PM,Newell DR,Harrap KR

    更新日期:1986-01-01 00:00:00

  • ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.

    abstract:PURPOSE:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent due to its selective cytotoxicity to transformed cells. However, most human hepatocellular carcinomas (HCC) develop resistance to TRAIL. Thus, there is an urgent need to investigate the molecular targets and the unde...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Wang G,Zhan Y,Wang H,Li W

    更新日期:2012-03-01 00:00:00

  • Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.

    abstract:BACKGROUND/AIMS:Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited. We compared the efficacy and safety of sorafenib and hepatic arterial infusion chemotherapy (HAIC). METHODS:In this randomized, prospecti...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Choi JH,Chung WJ,Bae SH,Song DS,Song MJ,Kim YS,Yim HJ,Jung YK,Suh SJ,Park JY,Kim DY,Kim SU,Cho SB

    更新日期:2018-09-01 00:00:00

  • Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.

    abstract:PURPOSE:To investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (SCLC) patients with pre-existing interstitial lung disease (ILD). METHODS:A total of 77 patients who received topotecan for the treatment of relapsed SCLC between April 2007 and April 2014 were reviewed. Patient...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Enomoto Y,Inui N,Imokawa S,Karayama M,Hasegawa H,Ozawa Y,Matsui T,Yokomura K,Suda T

    更新日期:2015-09-01 00:00:00

  • In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines.

    abstract:PURPOSE:To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines. METHODS:The human endometrial cancer cell lines, HEC-1-A and Ishikawa, were cultured in vitro. MTT assays were comple...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Navo MA,Smith JA,Gaikwad A,Burke T,Brown J,Ramondetta LM

    更新日期:2008-08-01 00:00:00

  • Synthesis of short retinoidal amides related to fenretinide: antioxidant activities and differentiation-inducing ability.

    abstract:PURPOSE:By a scaffold shortening strategy, a small series of retinoidal amides fenretinide (4-HPR) analogs have been synthesized from α, β-ionones and tested for their antiproliferative and differentiating activities, and antioxidant effect. METHODS:The antiproliferative activity and triggering of apoptosis of our sho...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Anzaldi M,Viale M,Macciò C,Castagnola P,Oliveri V,Rosano C,Balbi A

    更新日期:2017-04-01 00:00:00

  • Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis.

    abstract::We compared the safety and efficacy in mice with peritoneal carcinomatosis of two etoposide formulations: an aqueous solution (Etp-sol) and particles suspended in oil (the addition products of iodine and the ethyl esters of the fatty acids obtained from poppy-seed oil (Lipiodol) or sesame oil; Etp-oil). We also invest...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Lee JS,Takahashi T,Hagiwara A,Yoneyama C,Itoh M,Sasabe T,Muranishi S,Tashima S

    更新日期:1995-01-01 00:00:00

  • Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.

    abstract:PURPOSE:This exploratory phase II clinical trial evaluated the antitumor activity, safety profile and pharmacokinetics of PM00104 (Zalypsis(®)) 3 mg/m(2) 1 h every 3-week intravenous infusion in patients with advanced and/or metastatic urothelial carcinoma progressing after first-line platinum-based chemotherapy. METH...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Castellano DE,Bellmunt J,Maroto JP,Font-Pous A,Morales-Barrera R,Ghanem I,Suarez C,Martín Lorente C,Etxaniz O,Capdevila L,Coronado C,Alfaro V,Siguero M,Fernández-Teruel C,Carles J

    更新日期:2014-04-01 00:00:00

  • Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.

    abstract::Using flow cytometry and conventional spectrofluorimetry we have previously shown that chloroethylnitrosoureas (CNUs) can exhibit marked inhibition of cellular enzymes catalysing hydrolysis of fluorescein diacetate (FDA). More potent inhibition was seen for the carbamoylating CNUs, whereas alkylating agents were large...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Dive C,Workman P,Watson JV

    更新日期:1989-01-01 00:00:00

  • Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.

    abstract:PURPOSE:4'-Thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially useful guides for patient selection for...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Waud WR,Gilbert KS,Secrist JA 3rd

    更新日期:2011-08-01 00:00:00

  • Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

    abstract::Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/phys...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Greig NH,Soncrant TT,Shetty HU,Momma S,Smith QR,Rapoport SI

    更新日期:1990-01-01 00:00:00

  • Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.

    abstract:PURPOSE:ABT-888 inhibits poly(ADP-ribose) polymerase (PARP) and may enhance the efficacy of chemotherapy and radiation in CNS tumors. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration. METHODS:ABT-8...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Muscal JA,Thompson PA,Giranda VL,Dayton BD,Bauch J,Horton T,McGuffey L,Nuchtern JG,Dauser RC,Gibson BW,Blaney SM,Su JM

    更新日期:2010-02-01 00:00:00

  • Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.

    abstract:PURPOSE:Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Khawaja MR,Nick AM,Madhusudanannair V,Fu S,Hong D,McQuinn LM,Ng CS,Piha-Paul SA,Janku F,Subbiah V,Tsimberidou A,Karp D,Meric-Bernstam F,Lu KH,Naing A

    更新日期:2016-05-01 00:00:00

  • Randomized crossover antiemetic study in cisplatin-treated patients. Comparison between high-dose i.v. metoclopramide and high-dose i.v. dexamethasone.

    abstract::This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamethasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alon...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Frustaci S,Grattoni E,Tumolo S,Crivellari D,Figoli F,Galligioni E,Veronesi A,Tirelli U,Grigoletto E

    更新日期:1986-01-01 00:00:00

  • A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.

    abstract:PURPOSE:Capecitabine is an oral chemotherapeutic agent, already used in breast and colon cancer. Previous data showed encouraging results in the treatment of recurrent ovarian cancer. The aim of this study was to describe activity and toxicity of capecitabine in patients with platinum resistant or refractory ovarian ca...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究


    authors: Pisano C,Morabito A,Sorio R,Breda E,Lauria R,Gebbia V,Scaltriti L,Scalone S,Zagonel V,Greggi S,Beneduce G,Losito S,Gallo C,Di Maio M,Forestieri V,Pignata S

    更新日期:2009-10-01 00:00:00

  • Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme.

    abstract:PURPOSE:Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes ha...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Narita Y,Asai A,Kuchino Y,Kirino T

    更新日期:2000-01-01 00:00:00

  • Dosing algorithm revisit for busulfan following IV infusion.

    abstract:PURPOSE:Busulfan (Bu) exposure is critical for efficacy and safety. Body weight (BW), or adjusted ideal body weight (AIBW)-based dosing (WBD) algorithm, has been used in hematopoietic stem cell transplantation (HSCT). A recently completed phase 2 study revealed that 33.6 % of the subjects were under-, or over-exposed, ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Wang Y,Kato K,Le Gallo C,Armstrong E,Rock E,Wang X

    更新日期:2015-03-01 00:00:00

  • Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients.

    abstract:PURPOSE:Recently, based on results of the PACIFIC trial, durvalumab after chemoradiotherapy (CRT) became the standard therapy for unresectable stage III non-small cell lung cancer (NSCLC). However, in the PACIFIC trial, patients were recruited and randomized after CRT, and certain patients were considered ineligible af...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Hosoya K,Fujimoto D,Kawachi H,Sato Y,Kogo M,Nagata K,Nakagawa A,Tachikawa R,Hiraoka S,Kokubo M,Tomii K

    更新日期:2019-08-01 00:00:00

  • Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).

    abstract:PURPOSE:The sequence bendamustine (B) + Irinotecan (I) followed by etoposide (E) + carboplatin (C) was hypothesized to increase progression-free survival (PFS) and overall survival (OS) in untreated extensive-disease small cell lung cancer (EDSCLC) patients compared to historical controls by exploiting mitotic catastro...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Allendorf DJ,Bordoni RE,Grant SC,Saleh MN,Reddy VB,Jerome ML,Dixon PM,Miley DK,Singh KP,Robert F

    更新日期:2015-11-01 00:00:00

  • A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.

    abstract:PURPOSE:There is a need for effective chemotherapy protocols for gall bladder cancer (GBC). Gemcitabine has antitumor activity in pancreatic cancer. Oxaliplatin is effective in GI cancers. Based on evidence of synergy between these two, we designed this study to evaluate efficacy of this combination in unresectable GBC...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Sharma A,Mohanti B,Raina V,Shukla N,Pal S,Dwary A,Deo S,Sahni P,Garg P,Thulkar S,DattaGupta S,Rath G

    更新日期:2010-02-01 00:00:00

  • Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations.

    abstract::Hexadecylphosphocholine (HPC) and octadecylphosphocholine (OPC) show very potent antitumor activity against autochthonous methylnitrosourea-induced mammary carcinomas in rats. The longer-chain and unsaturated homologue erucylphosphocholine (EPC) forms lamellar structures rather than micelles, but nonetheless exhibits ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Kötting J,Berger MR,Unger C,Eibl H

    更新日期:1992-01-01 00:00:00

  • Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.

    abstract:PURPOSE:Epigenetic silencing of tumor suppressor genes (TSGs) by aberrant DNA methylation and chromatin deacetylation provides interesting targets for chemotherapeutic intervention by inhibitors of these events. 5-Aza-2'-deoxycytidine (decitabine, 5AZA-CdR) is a potent demethylating agent, which can reactivate TSGs sil...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Hurtubise A,Momparler RL

    更新日期:2006-11-01 00:00:00

  • Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells.

    abstract::The chemotherapeutic effects of all-trans-retinoic acid (atRA) are mediated by the retinoic acid receptor beta (RARbeta), but RARbeta expression is reduced in a number of head and neck carcinoma (HNSCC) cells which causes resistance to RA treatment in half the patients with HNSCC. The possible mechanism for the reduce...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Whang YM,Choi EJ,Seo JH,Kim JS,Yoo YD,Kim YH

    更新日期:2005-11-01 00:00:00

  • Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.

    abstract:BACKGROUND:Camptothecin (CPT) is an anticancer agent that kills cells by converting DNA topoisomerase I into a DNA-damaging agent. Although CPT and its derivatives are now being used to treat tumors in a variety of clinical protocols, the low water solubility of the drug and its unique pharmacodynamics and reactivity i...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Minko T,Paranjpe PV,Qiu B,Lalloo A,Won R,Stein S,Sinko PJ

    更新日期:2002-08-01 00:00:00

  • Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

    abstract::We have recently demonstrated that continuous-infusion (CI) 5-fluorouracil (FU) eradicates human colon carcinoma cells made resistant to bolus FU in vitro. In addition, in the same experimental system, the mechanisms of resistance to pulse and CI FU were found to be different. These observations led us to test the cli...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章


    authors: Mori A,Bertoglio S,Guglielmi A,Aschele C,Bolli E,Tixi L,Rosso R,Sobrero A

    更新日期:1993-01-01 00:00:00